Overexpression of Sulf2 in idiopathic pulmonary fibrosis

Glycobiology

Volumn 23, Issue 6, 2013, Pages 709-719

  Yue, Xinping ^a   Lu, Jingning ^a   Auduong, Linda ^a   Sides, Mark D ^b   Lasky, Joseph A ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

fibrosis; heparan sulfate; IPF; Sulf2; TGF 1

Indexed keywords

MESSENGER RNA; PROTEIN; SMAD PROTEIN; SMALL INTERFERING RNA; SULF1 PROTEIN; SULFATASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ALVEOLUS CELL TYPE 2; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

FIBROSIS; HEPARAN SULFATE; IPF; SULF2; TGF-Β1;

AGED; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELL LINE, TUMOR; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; HEPARITIN SULFATE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PNEUMOCYTES; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SMAD PROTEINS; SULFOTRANSFERASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84877269945     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt010     Document Type: Article

References (46)

1. Adamson IY, Bowden DH. 1974. The type 2 cell as progenitor of alveolar epithelial regeneration. A cytodynamic study in mice after exposure to oxygen. Lab Invest. 30:35-42.
2. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP, Jr. 2003. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol. 162:341-351.
3. Ai X, Kitazawa T, Do AT, Kusche-Gullberg M, Labosky PA, Emerson CP, Jr. 2007. SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development. 134:3327-3338.
4. Ask K, Martin GE, Kolb M, Gauldie J. 2006. Targeting genes for treatment in idiopathic pulmonary fibrosis: Challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc. 3:389-393.
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 68:729-777.
6. Buckley ST, Medina C, Kasper M, Ehrhardt C. 2011. Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol. 300:L548-L559.
7. Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, Bradshaw J, Linsley PS, Cleary MA. 2009. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res. 69:1368-1374.
8. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et al. 2003. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 162:1495-1502.
9. Corti M, Brody AR, Harrison JH. 1996. Isolation and primary culture of murine alveolar type II cells. Am J Respir Cell Mol Biol. 14:309-315.
10. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Blackwell TS, Lawson WE. 2010. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 299:L442-L452.
11. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP, Jr. 2001. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science. 293:1663-1666.
12. Esko JD, Lindahl U. 2001. Molecular diversity of heparan sulfate. J Clin Invest. 108:169-173.
13. Jinnin M, Ihn H, Tamaki K. 2006. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 69:597-607.
14. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. 2005. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 6:56.
15. Katzenstein AL, Mukhopadhyay S, Myers JL. 2008. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol. 39:1275-1294.
16. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH, Moses HL. 1988. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem. 263:3111-3115.
17. Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH. 1991. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 5:155-162.
18. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. 2006. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 103:13180-13185.
19. Kim R, Meyer KC. 2008. Therapies for interstitial lung disease: Past, present and future. Ther Adv Respir Dis. 2:319-338.
20. Kliment CR, Oury TD. 2010. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med. 49:707-717.
21. Klingsberg RC, Mutsaers SE, Lasky JA. 2010. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology. 15:19-31.
22. Konigshoff M. 2011. Lung cancer in pulmonary fibrosis: Tales of epithelial cell plasticity. Respiration. 81:353-358.
23. Konigshoff M, Eickelberg O. 2010. WNT Signaling in Lung Disease: A Failure or a Regeneration Signal Am J Respir Cell Mol Biol. 42:21-31.
24. Kottmann RM, Hogan CM, Phipps RP, Sime PJ. 2009. Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology. 14:917-933.
25. Lamanna WC, Baldwin RJ, Padva M, Kalus I, Ten Dam G, van Kuppevelt TH, Gallagher JT, von Figura K, Dierks T, Merry CL. 2006. Heparan sulfate 6-O-endosulfatases: Discrete in vivo activities and functional co-operativity. Biochem J. 400:63-73.
26. Lamanna WC, Kalus I, Padva M, Baldwin RJ, Merry CL, Dierks T. 2007. The heparanome-The enigma of encoding and decoding heparan sulfate sulfation. J Biotechnol. 129:290-307.
27. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD. 2010. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene. 29:635-646.
28. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402-408.
29. Lyon M, Gallagher JT. 1998. Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol. 17:485-493.
30. Lyon M, Rushton G, Gallagher JT. 1997. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J Biol Chem. 272:18000-18006.
31. Massague J. 2000. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 1:169-178.
32. McCaffrey TA, Falcone DJ, Du B. 1992. Transforming growth factor-beta 1 is a heparin-binding protein: Identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol. 152:430-440.
33. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. 2005. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia. 7:1001-1010.
34. Nakato H, Kimata K. 2002. Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim Biophys Acta. 1573:312-318.
35. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. 2007. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One. 2:e392.
36. Perrimon N, Bernfield M. 2001. Cellular functions of proteoglycans-An overview. Semin Cell Dev Biol. 12:65-67.
37. Phan SH. 2002. The myofibroblast in pulmonary fibrosis. Chest. 122: 286S-2289.
38. Ramos C, Becerril C, Montano M, Garcia-De-Alba C, Ramirez R, Checa M, Pardo A, Selman M. 2010. FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 299:L222-L231.
39. Rock JR, Barkauskas CE, Cronce MJ, Xue Y, Harris JR, Liang J, Noble PW, Hogan BL. 2011. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA. 108:E1475-E1483.
40. Selman M, Pardo A. 2006. Role of epithelial cells in idiopathic pulmonary fibrosis: From innocent targets to serial killers. Proc Am Thorac Soc. 3:364-372.
41. Shan B, Zhuo Y, Chin D, Morris CA, Morris GF, Lasky JA. 2005. Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells. J Biol Chem. 280:1103-1111.
42. Tang R, Rosen SD. 2009. Functional consequences of the subdomain organization of the sulfs. J Biol Chem. 284:21505-21514.
43. Willis BC, duBois RM, Borok Z. 2006. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc. 3:377-382.
44. Yanagisawa K, Osada H, Masuda A, Kondo M, Saito T, Yatabe Y, Takagi K, Takahashi T. 1998. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene. 17:1743-1747.
45. Yang IV, Burch LH, Steele MP, Savov JD, Hollingsworth JW, McElvania-Tekippe E, Berman KG, Speer MC, Sporn TA, Brown KK, et al. 2007. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med. 175:45-54.
46. Yue X, Li X, Nguyen HT, Chin DR, Sullivan DE, Lasky JA. 2008. Transforming growth factor-beta1 induces heparan sulfate 6-O-endosulfatase 1 expression in vitro and in vivo. J Biol Chem. 283:20397-20407.